List view / Grid view
Bavencio (avelumab) and Inlyta (axitinib) are recommended by NICE for…
Bavencio (avelumab) and Inlyta (axitinib) are recommended by NICE for the treatment of advanced renal cell carcinoma, available on the Cancer Drugs Fund.
NICE has decided to not recommend Mayzent (siponimod) for use…
NICE has decided to not recommend Mayzent (siponimod) for use on the NHS as a secondary progressive multiple sclerosis treatment because its clinical trial did not directly compare it to interferon beta-1b.
Larotrectinib has been given a positive opinion by NICE, following…
Larotrectinib has been given a positive opinion by NICE, following the submission of a revised price after it was previously rejected.
The UK’s National Institute for Health and Care Excellence, NICE,…
The UK’s National Institute for Health and Care Excellence, NICE, recommends the use of fremanezumab on the NHS for preventing chronic migraine.
NICE has given its positive opinion to lenalidomide in combination…
NICE has given its positive opinion to lenalidomide in combination with rituximab as a 'chemotherapy-free' treatment for lymphoma.
Esketamine nasal spray did not receive a positive opinion from…
Esketamine nasal spray did not receive a positive opinion from NICE due to inadequate comparisons to other therapies and concerns over its cost effectiveness.
The voretigene neparvovec gene therapy treatment has been highlighted in…
The voretigene neparvovec gene therapy treatment has been highlighted in draft guidance by NICE for availability on the NHS.
NICE and GW Pharma will work together to address the…
NICE and GW Pharma will work together to address the issues highlighted in its evaluation of cannabidiol for treating two types of epilepsy.
Vizimpro (dacomitinib) has been recommended as a first-line treatment option…
Vizimpro (dacomitinib) has been recommended as a first-line treatment option for patients with lung cancer.
A CAR-T immunotherapy for adults with an aggressive form of…
A CAR-T immunotherapy for adults with an aggressive form of non-Hodgkin lymphoma has been provisionally rejected by the NHS...
